Circular RNA_0003489 reflects unfavorable treatment response and shortened survival in newly diagnosed multiple myeloma patients who receive bortezomib-based induction therapy

Circular RNA_0003489 reflects unfavorable treatment response and shortened survival in newly diagnosed multiple myeloma patients who receive bortezomib-based induction therapy

Objectives Circular RNA_0003489 (Circ_0003489) promotes multiple myeloma (MM) progression and bortezomib resistance in MM cells, while its potential as a biomarker in newly diagnosed MM (NDMM) patients is unclear. Thus, this study aimed to investigate the association of circ_0003489 expression with...

Full description

Saved in:

Bibliographic Details
Main Authors:	Senhua Song, Junjie Xie, Biao Xu, Qijie Ran
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Hematology
Subjects:	Circular RNA_0003489 newly diagnosed multiple myeloma treatment response survival bortezomib-based induction therapy
Online Access:	https://www.tandfonline.com/doi/10.1080/16078454.2024.2399419
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Ixazomib combined with lenalidomide and dexamethasone chemotherapy for newly diagnosed multiple myeloma in China—Compared with bortezomib/lenalidomide/dexamethasone
by: Zhongjun Huo, et al.
Published: (2023-02-01)

Incidence, characteristics, and treatments of peripheral neuropathy in multiple myeloma patients receiving bortezomib (velcade)
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma
by: K. A. Belousov, et al.
Published: (2019-04-01)

Results of multiple myeloma treatment with bortezomib
by: T. I. Pospelova, et al.
Published: (2022-11-01)

Bortezomib neurotoxicity treatment of multiple myeloma: single center experience and literature review
by: N. V. Stepanova, et al.
Published: (2022-11-01)

Prevention and management of bortezomib-induced peripheral neuropathy in patients with multiple myeloma
by: S. V. Semochkin, et al.
Published: (2022-04-01)

Optimal daratumumab-based regimen for patients with newly diagnosed and previously untreated multiple myeloma: systematic review and component network meta-analysis
by: Xiaohua Huang, et al.
Published: (2025-05-01)

Tregs at Diagnosis as a Potential Biomarker for Predicting High‐Risk Functionality in Newly Diagnosed Multiple Myeloma
by: Qiaolin Zhou, et al.
Published: (2025-06-01)

Herpes zoster in multiple myeloma patients during bortezomib treatment
by: I. N. Nazarova, et al.
Published: (2014-07-01)

Efficacy of lenalidomide, bortezomib, and prednisolone in patients with relapsed or refractory multiple myeloma
by: T. A. Мitinа, et al.
Published: (2015-12-01)

Bortezomib (Velcade) in combination with dexamethasone eor relapsed or refractory myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Predictors of frontline doublet or triplet regimen initiation in transplant-ineligible newly diagnosed multiple myeloma
by: Matthew J. Pianko, et al.
Published: (2025-12-01)

Boanmycin overcomes bortezomib resistance by inducing DNA damage and endoplasmic reticulum functional impairment in multiple myeloma
by: Jin-Xing Wang, et al.
Published: (2025-01-01)

Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal plasmacytomas: a retrospective study in a single center
by: Shuiqing Xu, et al.
Published: (2024-12-01)

Insights into very elderly multiple myeloma treatment from Kansai Myeloma Forum
by: Yusuke Okayama, et al.
Published: (2025-12-01)

Doxorubicin synergizes bortezomib-induced multiple myeloma cell death by inhibiting aggresome formation and augmenting endoplasmic reticulum/Golgi stress and apoptosis
by: Chang-Tze Ricky Yu, et al.
Published: (2024-12-01)

Bortezomib, thalidomide, and dexamethasone versus thalidomide and dexamethasone for response rates in multiple myeloma patients: a retrospective study
by: Juan M. Cano-Calderón, et al.
Published: (2025-01-01)

Bortezomib (velcade) plus melphalan and prednisone in elderly untreated patients with multiple myeloma
by: S. S. Bessmeltsev, et al.
Published: (2022-11-01)

Comparison of 6 cycles of isatuximab with lenalidomide, bortezomib and dexamethasone (I-VRd) versus 3 cycles of I-VRd followed by one cycle of high-dose melphalan in newly diagnosed low-risk multiple myeloma. Protocol for a multicenter, prospective, randomized, phase II clinical trial (ELIAS-Trial)
by: Theo Leitner, et al.
Published: (2024-12-01)

MASS-4 is more suitable than MASS-3 for prognostic stratification in transplant-eligible patients with newly diagnosed multiple myeloma
by: Fan Yang, et al.
Published: (2025-12-01)

Bortezomib-based Chemotherapy and Bone-marrow Followed by Renal Transplantation in Multiple Myeloma: A Literature Review
by: Jasmine Sethi, et al.
Published: (2025-04-01)

Recombinant human thrombopoietin does not promote platelet engraftment in newly diagnosed multiple myeloma patients following autologous stem cell transplantation
by: Ruiqi Wang, et al.
Published: (2025-02-01)

The hidden costs of PEG-rhG-CSF in autologous stem cell transplantation for newly diagnosed multiple myeloma
by: Ruiqi Wang, et al.
Published: (2025-08-01)

NEWLY DIAGNOSED STROKE-ASSOCIATED ATRIAL FIBRILLATION: RISK OF DEVELOPMENT OF UNFAVORABLE CLINICAL OUTCOMES (THE RESULTS OF THE SUBANALYSIS COHORT STUDY APOLLO)
by: I. A. Zolotovskaya, et al.
Published: (2017-09-01)

The role of АВС transporters in drug resistance to bortezomib in multiple myeloma
by: L. A. Laletina, et al.
Published: (2019-04-01)

Dosing strategy of intrapleural bortezomib for myelomatous pleural effusion: A case report and review of literature
by: Yu‐Ming Li, et al.
Published: (2024-12-01)

Prognostic Value of PSMB5 and Correlations with LC3II and Reactive Oxygen Species Levels in the Bone Marrow Mononuclear Cells of Bortezomib-Resistant Multiple Myeloma Patients
by: Eva Plakoula, et al.
Published: (2025-01-01)

The prognostic value of the platelet-to-lymphocyte ratio in multiple myeloma patients treated with a bortezomib-based regimen
by: Quane Zhang, et al.
Published: (2025-01-01)

Intestinal Perforation Secondary to Bortezomib‐Induced Autonomic Neuropathy
by: Jose Antonio Sánchez Salas, et al.
Published: (2025-04-01)

Oxidative Stress Score as a Simplified Surrogate for Prognostic Stratification and Therapeutic Decision-Making in Multiple Myeloma
by: Qi Liang, et al.
Published: (2025-06-01)

Newly diagnosed atrial fibrillation detected by noninvasive screening methods in clinical practice
by: Luis Aguinaga, MD, MBA, PhD, RMFAC, FACC, FESC, et al.
Published: (2025-08-01)

Comparison of Time to Next Treatment or Death Between Front‐Line Daratumumab, Lenalidomide, and Dexamethasone (DRd) Versus Bortezomib, Lenalidomide, and Dexamethasone (VRd) Among Transplant‐Ineligible Patients With Multiple Myeloma
by: Doris K. Hansen, et al.
Published: (2024-11-01)

Tests of Attention in Newly Diagnosed Idiopathic Epilepsy
by: J Gordon Millichap
Published: (2002-04-01)

New proteasome inhibitors in the management of multiple myeloma
by: S. V. Semochkin
Published: (2019-07-01)

Bortezomib-releasing silica-collagen xerogels for local treatment of osteolytic bone- and minimal residual disease in multiple myeloma
by: Dirk Hose, et al.
Published: (2024-12-01)

Prognostic Factors in Newly Diagnosed High‐Grade Osteosarcoma—A Systematic Review
by: Elisa Tirtei, et al.
Published: (2025-07-01)

Role of BACH1 in multiple myeloma
by: Yan Chen, et al.
Published: (2024-12-01)

Interventions for promoting physical activity in people with newly diagnosed Parkinson’s disease: scoping review
by: Jonathan Gilby, et al.
Published: (2025-08-01)

Secondary Plasmacytoma of The Orbit In A Patient With Refractory Ig G Kappa Multiple Myeloma
by: Aruna Turaka
Published: (2014-04-01)

Pomalidomide in relapsed and refractory multiple myeloma: multicenter retrospective study
by: V. G. Potapenko, et al.
Published: (2022-07-01)